Black Rock Inc. Immuneering Corp Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Immuneering Corp stock. As of the latest transaction made, Black Rock Inc. holds 1,377,120 shares of IMRX stock, worth $1.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,377,120

Previous 2,097,406 34.34%

Holding current value

$1.91 Million

Previous $15.4 Million 74.19%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.91 - $7.32 $1.38 Million - $5.27 Million	-720,286 Reduced 34.34%	1,377,120 $3.98 Million
Q4 2023 Feb 13, 2024	SELL	$4.84 - $8.44 $2.01 Million - $3.5 Million	-414,612 Reduced 16.51%	2,097,406 $15.4 Million
Q3 2023 Nov 13, 2023	BUY	$7.21 - $10.68 $637,075 - $943,684	88,360 Added 3.65%	2,512,018 $19.3 Million
Q2 2023 Aug 11, 2023	BUY	$6.49 - $13.36 $7.03 Million - $14.5 Million	1,083,465 Added 80.84%	2,423,658 $24.6 Million
Q1 2023 May 12, 2023	SELL	$3.78 - $10.38 $30,961 - $85,022	-8,191 Reduced 0.61%	1,340,193 $13 Million

Q4 2022 Feb 13, 2023	SELL	$4.09 - $10.24 $309,408 - $774,656	-75,650 Reduced 5.31%	1,348,384 $6.54 Million
Q3 2022 Nov 14, 2022	BUY	$5.0 - $12.85 $336,820 - $865,627	67,364 Added 4.97%	1,424,034 $20.4 Million
Q2 2022 Aug 12, 2022	SELL	$3.89 - $7.81 $2.98 Million - $5.99 Million	-766,704 Reduced 36.11%	1,356,670 $7.34 Million
Q1 2022 May 12, 2022	BUY	$6.47 - $16.99 $2.63 Million - $6.92 Million	407,204 Added 23.73%	2,123,374 $13.7 Million
Q4 2021 Feb 10, 2022	BUY	$16.12 - $31.02 $3.09 Million - $5.95 Million	191,796 Added 12.58%	1,716,170 $27.8 Million
Q3 2021 Nov 09, 2021	BUY	$17.0 - $32.84 $25.9 Million - $50.1 Million	1,524,374 New	1,524,374 $40.5 Million

Others Institutions Holding IMRX

# of Institutions

Shares Held

11.6M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $36.7M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account